Grade B esophagitis sits in a clinically meaningful middle zone: it is serious enough that gastroenterologists now treat it as conclusive proof of gastroesophageal reflux disease, yet it typically responds well to standard acid-suppression therapy. Under the widely used Los Angeles classification system, Grade B means your endoscopist found one or more mucosal breaks longer than 5 mm that do not bridge adjacent mucosal folds. That puts it a step above the mildest form (Grade A) and below the more destructive grades C and D, where erosions wrap around larger sections of the esophageal lining. The practical picture, though, is more nuanced than a simple ranking.
What the Los Angeles Grading System Actually Measures
When a doctor threads a camera into your esophagus, they are looking at the lining where it meets the stomach. Acid reflux can erode that lining, and the Los Angeles (LA) classification describes how much damage is visible. Grade A is the mildest: small erosions under 5 mm that stay within a single mucosal fold. Grade B involves erosions longer than 5 mm, still confined to individual folds. Grade C means erosions have started connecting across folds but cover less than three-quarters of the esophageal circumference. Grade D is the most severe, with erosions wrapping around 75 percent or more of the circumference.1PubMed Central. The Los Angeles-B esophagitis is a conclusive diagnostic evidence for gastroesophageal reflux disease: the validation of Lyon Consensus 2.0
The distinction between Grade A and Grade B matters more than the 5 mm cutoff might suggest. Under the updated Lyon Consensus 2.0, Grade A esophagitis is considered borderline or inconclusive evidence of GERD on its own, because tiny erosions can sometimes be found in people without meaningful reflux disease. Grade B, however, is treated as conclusive diagnostic evidence of GERD, placing it in the same diagnostic tier as Barrett’s esophagus and peptic strictures.2Clinical Endoscopy. Endoscopic anti-reflux treatment for gastroesophageal reflux disease In practical terms, if your endoscopy report says LA Grade B, your doctor does not need additional pH monitoring or impedance testing to confirm you have GERD. That certainty shapes both the urgency of treatment and the confidence with which long-term management plans are made.
Symptoms May Not Match the Damage
One of the more frustrating aspects of erosive esophagitis is the loose relationship between the visible damage and how bad you feel. A prospective study comparing patients with milder grades (A and B) to those with more severe grades (C and D) found that overall symptom severity scores were only slightly different between the two groups. The clearest gap was in regurgitation: about 54 percent of patients with Grade C or D erosions reported above-median regurgitation scores, compared with roughly 35 percent of Grade A/B patients. Heartburn followed a similar but statistically weaker pattern.3Scientific Reports. Quality of life and severity of symptoms among patients with various degrees of reflux esophagitis: a prospective study
What this means for someone with Grade B: you may have classic heartburn and regurgitation, or your symptoms might be surprisingly mild. Some people discover their Grade B esophagitis only because they had an endoscopy for another reason entirely. A multicenter Chinese study found that patients whose low-grade esophagitis was initially asymptomatic were still more likely to develop GERD symptoms within a year if they had Grade B rather than Grade A, with 16 percent of Grade B patients developing symptoms versus about 8 percent of Grade A patients.4Gastroenterology Report. Clinical outcomes of asymptomatic low-grade esophagitis: results from a multicenter Chinese cohort Those patients also tended to have more severe esophagitis at follow-up endoscopy, suggesting Grade B is more likely to worsen over time if left untreated, even when it feels harmless at the start.
The Barrett’s Esophagus Question
One concern that people with erosive esophagitis reasonably have is the risk of Barrett’s esophagus, a condition where the normal esophageal lining is replaced by tissue that resembles the intestinal lining. Barrett’s matters because it is a precursor to esophageal adenocarcinoma, though the absolute risk of that cancer remains low even among Barrett’s patients. A study looking at patients with moderate to severe erosive esophagitis (LA grades B, C, and D combined) found Barrett’s in about 27 percent of that group.5PubMed Central. Prevalence of Barrett’s esophagus in patients with moderate to severe erosive esophagitis
That number deserves context. The study grouped B, C, and D together, so the 27 percent figure is not specific to Grade B alone. Grades C and D involve far more extensive erosion and are generally considered higher risk for Barrett’s than Grade B in isolation. Still, the fact that Grade B is lumped into that moderate-to-severe bracket in research tells you something about how clinicians view it: serious enough to warrant the same vigilance as the higher grades when screening for complications. If you have Grade B esophagitis, your doctor may recommend surveillance biopsies to check for Barrett’s, especially if you have other risk factors like long-standing reflux, obesity, or a family history of esophageal cancer.
How Well Treatment Works
The good news is that Grade B esophagitis generally heals with standard medical therapy. Proton pump inhibitors, the class of drugs that includes omeprazole, lansoprazole, and esomeprazole, are the first-line treatment. Studies in patients with erosive esophagitis show healing rates between 75 and 95 percent after eight weeks of PPI therapy, regardless of which specific PPI is used.6PubMed Central. Drug treatment strategies for erosive esophagitis in adults: a narrative review Grade B falls comfortably within that range; the lower end of healing rates tends to apply to the more severe grades, where tissue damage is more extensive and harder to resolve.
A newer class of acid-suppressing drugs, called potassium-competitive acid blockers, has shown even stronger results. Vonoprazan, one of these newer agents, was compared to lansoprazole (a standard PPI) in a large randomized trial of over 1,000 patients with erosive esophagitis. Vonoprazan healed about 93 percent of patients compared with roughly 85 percent for lansoprazole.7PubMed. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial Vonoprazan works through a different mechanism than PPIs, blocking acid secretion more quickly and maintaining suppression more consistently. For patients with Grade B esophagitis who do not fully heal on a PPI, switching to vonoprazan or a related drug may be a practical option, though most people respond well to the conventional approach.
The Relapse Problem
Healing and staying healed are different challenges. One of the more sobering findings about low-grade erosive esophagitis is how often symptoms return once treatment stops. In a study of patients with LA Grade A or B esophagitis who achieved complete symptom resolution after eight weeks of esomeprazole, about half experienced symptom relapse within just 12 weeks of switching to on-demand (as-needed) therapy.8Advances in Digestive Medicine. Risk factors for symptom relapse in patients with Los Angeles Grade A/B erosive esophagitis That 50 percent relapse rate is high enough that it changes how you should think about treatment. Grade B esophagitis is not typically a “take pills for two months and move on” condition. For many people, it requires ongoing management.
The duration of the initial treatment course also appears to matter. Research comparing four weeks of PPI therapy to eight weeks found that both durations produced similar rates of initial symptom resolution in patients with mild erosive esophagitis. But the patients who took PPIs for eight weeks had lower rates of relapse afterward.9PubMed. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis The practical takeaway: even though you might feel better after a few weeks on a PPI, completing the full eight-week course reduces the odds of your symptoms returning quickly.
Weight Loss and Lifestyle Changes
Medications are not the whole story. Body weight has a well-established connection to erosive esophagitis, and losing weight can meaningfully improve outcomes. A five-year follow-up study found that participants who reduced their BMI were more likely to see their erosive esophagitis resolve, with the effect scaling by how much weight they lost. Compared with people whose BMI did not decrease, those who dropped their BMI by one to two points had modestly better odds of resolution, while those who lost more than two BMI points roughly doubled their chances of the condition clearing up.10Gut and Liver. Weight Loss as a Nonpharmacologic Strategy for Erosive Esophagitis: A 5-Year Follow-up Study
The mechanism is straightforward: excess abdominal weight increases pressure on the stomach, which pushes acid upward through the lower esophageal sphincter. Losing weight reduces that mechanical pressure. For someone with Grade B esophagitis who is overweight, weight loss is one of the few interventions that addresses a root cause rather than just suppressing acid. Other commonly recommended lifestyle measures, like elevating the head of the bed, avoiding meals close to bedtime, and reducing intake of known reflux triggers, have weaker evidence behind them individually but are low-cost and unlikely to cause harm.
Sleep, Work, and Daily Life
Reflux-related sleep disruption is a complaint that rarely gets the attention it deserves. A large study of working-age adults in Korea found that erosive esophagitis was associated with poorer sleep quality, longer time to fall asleep, and more interrupted sleep in men, even after adjusting for factors like age, BMI, alcohol use, and smoking. Interestingly, the same association did not hold for women in the study.11Gut and Liver. The Relationship between Erosive Esophagitis and Sleep Issues in Working-Aged Koreans
The connection between reflux and poor sleep makes physiological sense: lying down removes gravity’s help in keeping stomach acid where it belongs, and nighttime reflux episodes can cause micro-awakenings even when you do not fully wake up. If you have Grade B esophagitis and find yourself sleeping poorly, tired during the day, or waking with a sore throat, your esophagitis may be a bigger contributor than you realize. Treating the reflux aggressively, including timing your PPI dose before dinner rather than before breakfast if nighttime symptoms are dominant, can sometimes resolve sleep problems that patients attributed to stress or insomnia.
Why Patients with Milder Grades Tend to Skip Treatment
There is a paradox in how people respond to their diagnosis. A prospective study comparing treatment adherence found that only about 14 percent of patients with Grade A or B esophagitis were non-adherent to their prescribed therapy, while roughly 41 percent of patients with Grades C or D were non-adherent.12PubMed Central. Comparison in Adherence to Treatment between Patients with Mild–Moderate and Severe Reflux Esophagitis: A Prospective Study At first glance this seems backward: you would expect people with worse disease to take their treatment more seriously. But the likely explanation is that patients with more severe erosions tend to have more dramatic symptoms, and once those symptoms improve on medication, they feel “cured” and stop. Meanwhile, patients with Grade A/B, whose symptoms may be milder to begin with, may take their pills more consistently precisely because their side-effect burden is low and the medication feels manageable.
The practical lesson is that adherence matters regardless of grade. Given the roughly 50 percent relapse rate within three months of stopping, patients with Grade B esophagitis who feel fine on medication should not take that as a sign the problem has resolved permanently. The feeling-fine part is the medication working, not the disease disappearing.
The Diagnostic Reliability Gap
One issue worth knowing about is that LA grading is not perfectly consistent between endoscopists. A post hoc analysis of clinical trial data found that when different physicians reviewed the same endoscopy images or videos, they agreed on the severity grade only about 43 percent of the time. Endoscopists performing the original procedure tended to assign more severe grades than independent adjudicators reviewing the images afterward. Agreement between individual adjudicators was moderate, and it improved substantially when weighted for how far apart the disagreements were (a one-grade difference being less concerning than a two-grade difference).13Oxford Academic (Diseases of the Esophagus). Interobserver agreement for the assessment of erosive reflux esophagitis: a post hoc analysis of clinical trial data
What this means practically: if your endoscopy report says Grade B, there is some chance that a different endoscopist looking at the same images might have called it Grade A or Grade C. The clinical implications of this ambiguity are most significant at the A-to-B boundary, because that is where the diagnostic line falls between “inconclusive” and “conclusive” evidence of GERD under current guidelines. If your report says Grade A and you have persistent symptoms, it may be worth discussing with your doctor whether the findings could reasonably represent Grade B, which would change the diagnostic certainty and potentially the treatment approach.
The Financial Side
Erosive esophagitis carries a real economic burden. A national retrospective cohort study in the United States found that average total all-cause healthcare costs among patients who underwent endoscopy for erosive esophagitis were roughly $58,700 per patient, with about $4,300 of that directly attributable to the esophagitis itself.14PubMed Central. Economic and treatment burden among newly diagnosed patients with erosive esophagitis in the US: a national retrospective cohort study The large gap between all-cause and disease-specific costs reflects the reality that people with erosive esophagitis often have other health conditions (obesity, cardiovascular disease, diabetes) that drive up overall spending. Still, the disease-specific costs alone, which include endoscopies, medications, and follow-up visits, are not trivial, particularly for patients who require ongoing PPI therapy or repeated endoscopic surveillance.
For someone with Grade B esophagitis, the cost picture is shaped heavily by whether the condition is a one-time treatment course or a chronic management issue. If an eight-week PPI course heals the esophagus and lifestyle changes keep it healed, costs are modest. If symptoms relapse repeatedly, each cycle of re-evaluation and retreatment adds up. Generic PPIs are inexpensive, but the endoscopies and specialist visits that punctuate the management of recurring erosive esophagitis are not.
When Grade B Might Not Actually Be GERD
Although Grade B esophagitis is treated as conclusive evidence of GERD under current consensus guidelines, a small number of patients with esophageal erosions have a different underlying cause. Eosinophilic esophagitis, an immune-mediated condition where white blood cells accumulate in the esophageal lining, can produce mucosal changes that mimic reflux damage. Pill esophagitis, caused by medications like bisphosphonates, doxycycline, or potassium supplements that irritate the lining on the way down, is another mimic. Infections in immunocompromised patients can also cause erosive changes.
These alternative diagnoses are uncommon in someone with a classic Grade B presentation, but they become more relevant when the expected treatment does not work. If you have been on a full-dose PPI for eight weeks and your esophagitis has not healed, or if your symptoms include difficulty swallowing or food impaction rather than typical heartburn, your doctor may revisit the diagnosis with biopsies or additional testing. The LA grading system describes what the erosion looks like, not what caused it, and the assumption that the cause is acid reflux, while usually correct, is not always right.